Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04215978




Registration number
NCT04215978
Ethics application status
Date submitted
30/12/2019
Date registered
2/01/2020
Date last updated
8/10/2024

Titles & IDs
Public title
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Scientific title
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Secondary ID [1] 0 0
2022-501177-39-00
Secondary ID [2] 0 0
BGB-A317-A445-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumor 0 0
Non Small Cell Lung Cancer 0 0
Head and Neck Squamous Cell Carcinoma (HNSCC) 0 0
Nasopharyngeal Carcinoma (NPC) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Head and neck

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BGB-A445
Treatment: Drugs - tislelizumab

Experimental: Phase 1a: BGB-A445 Monotherapy - Dose Escalation Part A: Participants will receive intravenous (IV) infusion of BGB-A445 in sequential cohorts of approximately 8 increasing dose levels on day 1 of each 21-day cycle

Experimental: Phase 1a: BGB-A445 + Tislelizumab Combination Therapy - Dose Escalation Part B: Participants will receive IV infusion of BGB-A445 in sequential cohorts of approximately 6 increasing dose levels plus 200mg tislelizumab on day 1 of each 21-day cycle

Experimental: Phase 1b:BGB-A445 Monotherapy - Dose Expansion Part A: Participants will receive recommended doses of IV BGB-A445 as determined from Phase 1a Dose Escalation; BGB-A445 will be evaluated in two tumor types

Experimental: Phase 1b: BGB-A445 + Tislelizumab and Chemotherapy Combination Therapy - Dose Expansion Part B: Participants will receive recommended dose IV infusion of BGB-A445 plus 200mg tislelizumab and chemotherapy

Experimental: Phase 1b: BGB-A445 Monotherapy - Dose Expansion Part C: Participants will receive 1 dose level of BGB-A445


Treatment: Drugs: BGB-A445
Administered as specified in the treatment arm

Treatment: Drugs: tislelizumab
Administered as specified in the treatment arm
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Phase 1a: Number of Participants Experiencing Adverse Events (AEs)
Timepoint [1] 0 0
Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
Primary outcome [2] 0 0
Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)
Timepoint [2] 0 0
Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
Primary outcome [3] 0 0
Phase 1a: Number of Participants Experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria
Timepoint [3] 0 0
Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
Primary outcome [4] 0 0
Phase 1a: Maximum Tolerated Dose (MTD) of BGB-A445
Timepoint [4] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Primary outcome [5] 0 0
Phase 1b: RP2D of BGB-A445 when Administered Alone
Timepoint [5] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Primary outcome [6] 0 0
Phase 1b: Overall Response Rate (ORR) as Assessed by the Investigator
Timepoint [6] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [1] 0 0
Phase 1a: Overall Response Rate (ORR) as Assessed by the Investigator
Timepoint [1] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [2] 0 0
Phase 1a: Duration of Response (DOR) as Assessed by the Investigator
Timepoint [2] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [3] 0 0
Phase 1a: Disease-Control Rate (DCR) as Assessed by the Investigator
Timepoint [3] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [4] 0 0
Phase 1a: Serum Concentration of BGB-A445
Timepoint [4] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [5] 0 0
Phase 1a: Serum Concentration of tislelizumab
Timepoint [5] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [6] 0 0
Phase 1a: Maximum Observed Plasma Concentration (Cmax) of BGB-A445
Timepoint [6] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [7] 0 0
Phase 1a: Maximum Observed Plasma Concentration (Cmax) of tislelizumab
Timepoint [7] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [8] 0 0
Phase 1a: Minimum Observed Plasma Concentration (Cmin) of BGB-A445
Timepoint [8] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [9] 0 0
Phase 1a: Minimum Observed Plasma Concentration (Cmin) of tislelizumab
Timepoint [9] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [10] 0 0
Phase 1a: Time to Maximum Plasma Concentration (Tmax) of BGB-A445
Timepoint [10] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [11] 0 0
Phase 1a: Time to Maximum Plasma Concentration (Tmax) of tislelizumab
Timepoint [11] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [12] 0 0
Phase 1a: Area Under the Concentration-Time Curve of 0-21 Days (AUC0-21d) of BGB-A445
Timepoint [12] 0 0
60 minutes predose up to 21 days postdose
Secondary outcome [13] 0 0
Phase 1a: Immunogenic Responses to BGB-A445 as assessed through the detection of antidrug antibodies
Timepoint [13] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [14] 0 0
Phase 1a: Immunogenic Responses to tislelizumab as assessed through the detection of antidrug antibodies
Timepoint [14] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [15] 0 0
Phase 1b: Progression-free survival (PFS) as Assessed by the Investigator
Timepoint [15] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [16] 0 0
Phase 1b: Duration of Response (DOR) as Assessed by the Investigator
Timepoint [16] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [17] 0 0
Phase 1b: Disease-Control Rate (DCR) as Assessed by the Investigator
Timepoint [17] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first
Secondary outcome [18] 0 0
Phase 1b: Number of Participants Experiencing Adverse Events (AEs)
Timepoint [18] 0 0
Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
Secondary outcome [19] 0 0
Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs)
Timepoint [19] 0 0
Up to 90 days after the last dose of study drug(s) regardless of whether the participant starts a subsequent anticancer therapy
Secondary outcome [20] 0 0
Phase 1b: Serum Concentration of BGB-A445
Timepoint [20] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [21] 0 0
Phase 1b: Maximum Observed Plasma Concentration (Cmax) of BGB-A445
Timepoint [21] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [22] 0 0
Phase 1b: Minimum Observed Plasma Concentration (Cmin) of BGB-A445
Timepoint [22] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [23] 0 0
Phase 1b: Time to Maximum Plasma Concentration (Tmax) of BGB-A445
Timepoint [23] 0 0
60 minutes predose up to 72 hours postdose
Secondary outcome [24] 0 0
Phase 1b: Area Under the Concentration-Time Curve of 0-21 Days (AUC0-21d) of BGB-A445
Timepoint [24] 0 0
60 minutes predose up to 21 days postdose
Secondary outcome [25] 0 0
Phase 1b: Immunogenic Responses to BGB-A445 as assessed through the detection of antidrug antibodies
Timepoint [25] 0 0
Up to 30 days after the last dose of study drug(s) or before the initiation of a new anticancer treatment, whichever occurs first

Eligibility
Key inclusion criteria
Key

1. Phase 1a (dose escalation): Participants with histologically or cytologically confirmed advanced, metastatic, unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available, not tolerated or refused.

1. Enrollment will be limited to participants with advanced solid tumors for which there is clinical evidence of response to T cell based immuno-oncology agents (eg, anti PD 1) or other scientific evidence in support of an immunologically sensitive tumor type.
2. Participant has not received prior therapy targeting OX40 or any other T cell agonist therapy (prior checkpoint inhibitor therapy is allowed)

2. Phase 1b, the dose expansion phase, aims to include participants in specific tumor type cohorts who do not have access to standard systemic treatment, cannot tolerate it, or it is deemed inappropriate by the investigator. Cohort 1 focuses on non-small cell lung cancer (NSCLC) patients with advanced or metastatic disease, while Cohort 2 involves individuals with recurrent or metastatic head and neck squamous cell cancer (HNSCC). Cohort 3 includes participants with nasopharyngeal carcinoma (NPC), and Cohort 4 is for NSCLC patients with PD-L1 expression of at least 50%. Each cohort has specific eligibility criteria related to prior therapies, tumor characteristics, and treatment-free intervals.

3. Has at least 1 measurable lesion as defined per RECIST 1.1. The target lesion(s) selected have not been previously treated with local therapy OR the target lesion(s) selected that are within the field of prior local therapy have subsequently progressed as defined by RECIST 1.1 4. Participants should be able to provide tumor tissue sample 5. Eastern Cooperative Oncology Group (ECOG) Performance Status = 1 and a life expectancy of = 6 months.

6. Adequate organ function as indicated by the following laboratory values up to first dose of study drug

a. Participants must not have required blood transfusion or growth factor support = 14 days before sample collection for the following:

* Absolute neutrophil count = 1.5 x 10^9/L
* Platelet count = 75 x 10^9/L
* Hemoglobin = 90 g/L

b. Estimated glomerular filtration rate (GFR) = 60 mL/min/1.73 m^2 determined by the Cockcroft-Gault formula without correction for body surface area (BSA)
* The estimated GFR for participants with renal cell carcinoma must be = 30 mL/min/1.73 m^2 by the Cockcroft-Gault formula

c. Serum total bilirubin = 1.5 x ULN (< 3 x ULN for participants with Gilbert syndrome) d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN;
* = 5 x ULN for participants with hepatocellular carcinoma or liver metastases

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Active leptomeningeal disease or uncontrolled brain metastasis. Participants with equivocal findings or with confirmed brain metastases are eligible for enrollment provided they are asymptomatic and radiologically stable without the need for corticosteroid treatment for at least 4 weeks prior to the first dose of study drug(s)
2. Active autoimmune diseases or history of autoimmune diseases that may relapse or history of life-threatening toxicity related to prior immune therapy, with the following exceptions:

1. Controlled type 1 diabetes
2. Hypothyroidism (provided it is managed with hormone-replacement therapy only)
3. Controlled celiac disease
4. Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, or alopecia)
5. Any other disease that is not expected to recur in the absence of external triggering factors (requires consultation with the medical monitor prior to enrollment)
3. Any active malignancy = 2 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast)
4. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication = 14 days before the first dose of study drug(s), with the following exceptions:

1. Adrenal replacement steroid (dose = 10 mg daily of prednisone or equivalent)
2. Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption
3. Short course (= 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a nonautoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen)
5. Any major surgical procedure occurring = 28 days before the first dose of study drug(s). If surgical procedure occurs > 28 days, they must have recovered adequately from the toxicity

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/01/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
29/11/2024
Actual
Sample size
Target
Accrual to date
Final
342
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Blacktown Cancer And Haematology Centre - Blacktown
Recruitment hospital [2] 0 0
Pindara Private Hospital - Benowa
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment hospital [4] 0 0
Monash Health - Clayton
Recruitment hospital [5] 0 0
Peter Maccallum Cancer Centre - Melbourne
Recruitment hospital [6] 0 0
Nucleus Network - Melbourne
Recruitment hospital [7] 0 0
Linear Clinical Research - Nedlands
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
4217 - Benowa
Recruitment postcode(s) [3] 0 0
4102 - Brisbane
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
3000 - Melbourne
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Pennsylvania
Country [3] 0 0
China
State/province [3] 0 0
Hubei
Country [4] 0 0
China
State/province [4] 0 0
Hunan
Country [5] 0 0
China
State/province [5] 0 0
Shandong
Country [6] 0 0
China
State/province [6] 0 0
Shanghai
Country [7] 0 0
China
State/province [7] 0 0
Zhejiang
Country [8] 0 0
Korea, Republic of
State/province [8] 0 0
Gyeonggi-do
Country [9] 0 0
Korea, Republic of
State/province [9] 0 0
Gyeonggido
Country [10] 0 0
Korea, Republic of
State/province [10] 0 0
Seoul Teugbyeolsi
Country [11] 0 0
Malaysia
State/province [11] 0 0
Kuala Lumpur
Country [12] 0 0
Malaysia
State/province [12] 0 0
Kuching
Country [13] 0 0
New Zealand
State/province [13] 0 0
Auckland
Country [14] 0 0
Taiwan
State/province [14] 0 0
NAP
Country [15] 0 0
Taiwan
State/province [15] 0 0
Tainan
Country [16] 0 0
Thailand
State/province [16] 0 0
Bangkok
Country [17] 0 0
Thailand
State/province [17] 0 0
Muang

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.
Trial website
https://clinicaltrials.gov/study/NCT04215978
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
BeiGene
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04215978